Stock Analiz

Dyadic International Inc. DYAI

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.33Market cap $13M
Open the interactive analysis →

Dyadic International Inc. (DYAI) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$7M, a net margin of -226.9%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 14% a year, a 5-year average ROIC of -175%.

About Dyadic International

Dyadic International is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $758420 in 2017 to $3M in 2025, growth of about 19.2% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 15% over three years (dilution for shareholders). It spends 70% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-53.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-11.6%
Revenue growth (5 yrs, per year)14.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-303.0%
ROIC (5-yr avg.)-174.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$3M$3M$3M$3M$3M$2M$2M$2M$1M$758420
Net income-$7M-$7M-$6M-$7M-$10M-$13M-$9M-$8M-$6M-$2M
Free cash flow-$7M-$6M————————
EPS (diluted)$-0.20$-0.23$-0.20$-0.24$-0.34$-0.47$-0.34$-0.31$-0.21$-0.07
Net margin-226.9%-238.3%-166.2%-234.4%-332.2%-543.7%-582.1%-494.2%-439.4%-281.6%
ROIC—-448.5%-182.2%-108.1%-72.4%-63.3%-27.8%-20.4%-14.1%-11.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $4.50, 1276% above the current price; targets range from $2.00 to $7.00; the consensus rating is “Strong buy”; expected EPS is $-0.19 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Dyadic International pay a dividend?

Not currently.

Is Dyadic International a good stock to buy?

We do not give buy or sell advice. Dyadic International scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.